Gliclazide

Jump to: navigation, search
Gliclazide
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H21N3O3S
Molar mass323.412 g/mol

WikiDoc Resources for Gliclazide

Articles

Most recent articles on Gliclazide

Most cited articles on Gliclazide

Review articles on Gliclazide

Articles on Gliclazide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gliclazide

Images of Gliclazide

Photos of Gliclazide

Podcasts & MP3s on Gliclazide

Videos on Gliclazide

Evidence Based Medicine

Cochrane Collaboration on Gliclazide

Bandolier on Gliclazide

TRIP on Gliclazide

Clinical Trials

Ongoing Trials on Gliclazide at Clinical Trials.gov

Trial results on Gliclazide

Clinical Trials on Gliclazide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gliclazide

NICE Guidance on Gliclazide

NHS PRODIGY Guidance

FDA on Gliclazide

CDC on Gliclazide

Books

Books on Gliclazide

News

Gliclazide in the news

Be alerted to news on Gliclazide

News trends on Gliclazide

Commentary

Blogs on Gliclazide

Definitions

Definitions of Gliclazide

Patient Resources / Community

Patient resources on Gliclazide

Discussion groups on Gliclazide

Patient Handouts on Gliclazide

Directions to Hospitals Treating Gliclazide

Risk calculators and risk factors for Gliclazide

Healthcare Provider Resources

Symptoms of Gliclazide

Causes & Risk Factors for Gliclazide

Diagnostic studies for Gliclazide

Treatment of Gliclazide

Continuing Medical Education (CME)

CME Programs on Gliclazide

International

Gliclazide en Espanol

Gliclazide en Francais

Business

Gliclazide in the Marketplace

Patents on Gliclazide

Experimental / Informatics

List of terms related to Gliclazide


Overview

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. It is marketed as Diamicron MR®. DIAMICRON MR is also distributed as: Diabeton MR, Diamicron 30mg, Diamicron LM 30mg, Diamicron MR 30 mg, Diamicron Uno 30mg, Dianormax MR, Diaprel MR and Uni Diamicron.

Form and Composition:

Each tablet contains 80 mg of gliclazide.

Not marketed in the United States.

Indication:

Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate.

Dosage:

40 to 240 mg depending on response, once or twice daily before food, no more that 160 mg at a time.

Properties:

Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity. Glycemia-independent hemovascular effects, antioxidant effect. No active circulating metabolites.

Contraindications:

type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, pregnancy and lactation, miconazole coprescription.

Interactions:

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, possibly ACE inhibitors.

Adverse effects:

Hypoglycemia, gastrointestinal disturbance (reported), skin reactions (rare), hematological disorders (rare), hepatic enzyme rises (exceptional).

Overdosage:

Possible severe hypoglycemia requiring urgent IV glucose and monitoring.

External links



Linked-in.jpg